hotspot -WSS

hotspot

author：leisure time 2025-08-26 04:21:33 - browse：262

Nick Leschly - Bluebird Bio — Longtime Bluebird Bio CEO Nick Leschly Wendy Maeda/The Boston Globe

Some two years after splitting biotech company Bluebird Bio into two entities in a bid to “sharpen their focus” and improve operations, the spinout focused on oncology treatments announced major cost cuts and is parting ways with its chief executive.

The spinout, 2Seventy Bio, announced Tuesday that it is cutting approximately 40% of its workforce, or about 176 employees. It also plans to allocate less money to a couple of drug candidates, including one that is currently on hold with the Food and Drug Administration. The cuts extend the company’s cash runway into 2026.

The company was formed in 2021 when the team behind Bluebird Bio decided to split its drug pipeline down the middle. The company was wrestling with its gene therapy portfolio, including getting approval for a gene therapy for the blood disorder beta thalassemia in the U.S. Separately, it had a basket of cancer drug candidates and a partnership with pharma company Bristol Myers Squibb that needed attention. So, Bluebird split its operations in two, with longtime CEO Nick Leschly taking the helm at the new firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Annovis Bio delivers candor, but not confidence, on Parkinson’s study

WSS

In utero gene editing: an explainer

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Illinois to ban advertising for guns allegedly marketed to kids and militants

Moderna hits safety problems in bold bid to reinvent medicine

'The Exorcist' director William Friedkin dead at 87

He's a Nobel laureate. Critics say he was misleading on Covid

focus

hotspot

hotspot

Cancer drug shortages should be causing more outrage

The Harvard botanist who searched for psychedelics in the Amazon

Medical leaders decry Supreme Court decision on affirmative action

Community Health Systems hospitals under DOJ investigation

Drug repurposing or repositioning? The language matters

With competition flaring, obesity drug hits goal in liver disease study

Guidelines to prevent youth baseball injuries need more muscle

With competition flaring, obesity drug hits goal in liver disease study

Bright Health sells Medicare Advantage business to Molina

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

hotspot

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

STAT readers on older presidents, polypills, Medicare, and more

Democratic lawmaker calls for 'well

New documents shed light on MD Anderson Cancer Institute feud

A solution to the after

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

hotspot

hotspot

focus